Comparing systemic lidocaine and adductor canal block for knee surgery pain management
The Efficacy of Systemic Lidocaine Versus Ultrasound-guided Adductor Canal Block for Patients Undergoing Total Knee Arthroplasty: a Randomized, Double-blinded, Non-inferiority Study
This study is testing whether using systemic lidocaine or an adductor canal block helps people manage pain better after knee surgery and reduces the need for opioids.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Rhode Island Hospital Academic / other |
| Locations | 1 site (Providence, Rhode Island) |
| Trial ID | NCT04828083 on ClinicalTrials.gov |
What this trial studies
This study evaluates the postoperative outcomes of patients undergoing total knee arthroplasty who receive either systemic lidocaine or an ultrasound-guided adductor canal block as part of their anesthetic plan. The goal is to determine if there is a significant difference in pain management and opioid consumption between the two methods. Patients will be monitored for 24 hours post-surgery to assess their analgesia needs and overall recovery. This research aims to provide insights into effective pain management strategies, especially in settings where adductor canal blocks may not be feasible.
Who should consider this trial
Good fit: Ideal candidates are ASA PS 1-3 patients scheduled for primary, unilateral total knee arthroplasty.
Not a fit: Patients with ASA PS classification of 4 or greater, pre-existing neuropathy, or chronic opioid consumption may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide an effective pain management alternative that reduces opioid use for patients undergoing knee surgery.
How similar studies have performed: Previous studies have shown promising results with systemic lidocaine in various surgical settings, but direct comparisons with adductor canal blocks are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ASA PS 1-3 patients undergoing primary, unilateral total knee arthroplasty Exclusion Criteria: * ASA PS classification of 4 or greater * Pre-existing neuropathy * Coagulopathy * Chronic opioid consumption (\>3 months) * Infection at the site * Known allergy to study medications (lidocaine) * High grade atrioventricular block (cardiac conduction system impairment) * A history of CVA/TIA * Currently using lidocaine patches * Known liver disease
Where this trial is running
Providence, Rhode Island
- Rhode Island Hospital — Providence, Rhode Island, United States (Recruiting)
Study contacts
- Principal investigator: Vendhan Ramanujam, M.D. — Rhode Island Hospital, Brown University
- Study coordinator: Vendhan Ramanujam, M.D.
- Email: vramanujam@lifespan.org
- Phone: 401-444-5172
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.